Download Image
    
Share
  
Post
Ramipril for COVID-19
1 study with 114 patients
Hospital Icon Control
Hospital Icon Ramipril Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Ramipril studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -144% Mortality -144% RCTs -144% Late -144% Favorsramipril Favorscontrol
Ramipril is an oral small molecule angiotensin-converting enzyme (ACE) inhibitor that blocks the renin-angiotensin-aldosterone system (RAAS). Recent:
Huang.
Aug 24
2023
 Huang et al., Advances in Therapy, doi:10.1007/s12325-023-02618-7 Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
144% higher mortality (p=1), 289% higher ventilation (p=1), 289% higher ICU admission (p=1), and 144% lower hospital discharge (p=1). RCT 114 non-critically ill COVID-19 patients in the USA showing no significant differences with ramipril treatment.